#Bluejay #BluejayTherapeutics #phase3trial #brelovitug #BJT778 #hepatitisD #AZURE2study #CHD #hepatitisDvirus #cirrhosis #livercancer #viralhepatitis #liverdisease #BreakthroughTherapydesignation #FDA #PRIMEdesignation #Orphanstatus #OrphanDrug #EMA
pharmatimes.com/news/bluejay...
pharmatimes.com/news/bluejay...
Bluejay begins phase 3 trial of brelovitug for hepatitis D - PharmaTimes
First patient enrolled in AZURE-2 study comparing brelovitug to Hepcludex
pharmatimes.com
September 10, 2025 at 12:03 PM
Nurix Therapeutics has Received FDA’s Fast Track Designation for NX-5948 in Waldenstrom’s Macroglobulinemia
oncodaily.com/drugs/nurix-...
#Cancer #EMA #PRIMEDesignation #FDA #Medicine #FastTrackDesignation #NurixTherapeutics #OncoDaily #Oncology #Health
oncodaily.com/drugs/nurix-...
#Cancer #EMA #PRIMEDesignation #FDA #Medicine #FastTrackDesignation #NurixTherapeutics #OncoDaily #Oncology #Health
Nurix Therapeutics has Received FDA’s Fast Track Designation for NX-5948 in Waldenstrom’s Macroglobulinemia - OncoDaily
Nurix Therapeutics has Received FDA’s Fast Track Designation for NX-5948 in Waldenstrom’s Macroglobulinemia / Arthur T. Sands, cancer, EMA PRIME Designation,
oncodaily.com
December 24, 2024 at 5:36 PM
Nurix Therapeutics has Received FDA’s Fast Track Designation for NX-5948 in Waldenstrom’s Macroglobulinemia
oncodaily.com/drugs/nurix-...
#Cancer #EMA #PRIMEDesignation #FDA #Medicine #FastTrackDesignation #NurixTherapeutics #OncoDaily #Oncology #Health
oncodaily.com/drugs/nurix-...
#Cancer #EMA #PRIMEDesignation #FDA #Medicine #FastTrackDesignation #NurixTherapeutics #OncoDaily #Oncology #Health